Trials / Completed
CompletedNCT04721821
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Comparative Effectiveness of Tumor Necrosis Factor (TNF) Inhibitors and Tofacitinib, Overall, by Line of Therapy and by Combination Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7,807 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate if there has been a shift in treatment with tofacitinib, assessing real world patient data and entered in the Corrona registry between 2016 and 2020.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib | Patients who received Tofacitinib for RA |
Timeline
- Start date
- 2021-01-22
- Primary completion
- 2021-11-29
- Completion
- 2021-11-29
- First posted
- 2021-01-25
- Last updated
- 2024-04-12
- Results posted
- 2024-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04721821. Inclusion in this directory is not an endorsement.